Posaconazole
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication.
Clinical data | |
---|---|
Trade names | Noxafil, Posanol, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607036 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Low (8 to 47% Oral) |
Protein binding | 98 to 99% |
Metabolism | Liver (glucuronidation) |
Elimination half-life | 16 to 31 hours |
Excretion | Fecal (71–77%) and Kidney (13–14%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.208.201 |
Chemical and physical data | |
Formula | C37H42F2N8O4 |
Molar mass | 700.792 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
It was approved for medical use in the United States in September 2006, and is available as a generic medication.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.